ARMP EBITDA | ARMATA PHARMACEUTICALS, INC.

ARMATA PHARMACEUTICALS, INC. (ARMP) EBITDA

2026-06-30: Basis Reported; EBITDA (m); Operating income -$10.31M; Depreciation and amortization (m).
2026-03-31: Basis Reported; EBITDA (m); Operating income -$8.79M; Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA -$7.41M*; Operating income -$7.78M; Depreciation and amortization $370.00K*.
2025-06-30: Basis Reported; EBITDA -$6.48M*; Operating income -$6.84M; Depreciation and amortization $366.00K*.

Complete source-backed ebitda history.

Available history: 2022-12-31 to 2025-03-31
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	(m)	-$10.31M	(m)	(m)	(m)	$17.00K*	-$8.67M*	(m)	(m)	(m)	$0.00*
2026-03-31	Reported	(m)	-$8.79M	(m)	(m)	(m)	$63.00K	-$5.78M	(m)	(m)	(m)	$0.00
2025-09-30	Reported	-$7.41M*	-$7.78M	$370.00K*	(m)	(m)	$242.00K*	-$4.30M*	(m)	(m)	(m)	$0.00
2025-06-30	Reported	-$6.48M*	-$6.84M	$366.00K*	(m)	(m)	$149.00K*	-$7.21M*	(m)	(m)	(m)	$0.00*
2025-03-31	Reported	-$7.81M	(m)	(m)	(m)	(m)	$99.00K	-$7.58M	(m)	(m)	(m)	$0.00
2024-12-31	Reported	-$10.16M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2024-09-30	Reported	-$9.44M*	-$9.76M	$313.00K*	(m)	(m)	$340.00K*	-$8.86M*	(m)	(m)	(m)	$0.00
2024-06-30	Reported	-$11.60M*	-$11.91M	$315.00K*	(m)	(m)	$1.37M*	-$10.18M*	(m)	(m)	(m)	$0.00
2024-03-31	Reported	-$9.91M	(m)	(m)	(m)	(m)	$250.00K	-$10.58M	(m)	(m)	(m)	$0.00
2023-12-31	Reported	-$9.29M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2023-09-30	Reported	-$10.12M*	-$10.34M	$221.00K*	(m)	(m)	$3.51M*	-$9.69M*	(m)	(m)	(m)	$0.00
2023-06-30	Reported	-$9.40M*	-$9.63M	$228.00K*	(m)	(m)	$222.00K*	-$12.06M*	(m)	(m)	(m)	$0.00
2023-03-31	Reported	-$11.12M	(m)	(m)	(m)	(m)	$2.01M	-$17.57M	(m)	(m)	(m)	$0.00
2022-09-30	Reported	(m)	-$8.62M	(m)	(m)	(m)	$1.29M*	-$10.33M*	(m)	(m)	(m)	$0.00
2022-06-30	Reported	(m)	-$9.22M	(m)	(m)	(m)	$1.14M*	-$8.15M*	(m)	(m)	(m)	$0.00
2022-03-31	Reported	(m)	-$8.78M	(m)	(m)	(m)	$236.00K	-$3.52M	(m)	(m)	(m)	$0.00
2021-09-30	Reported	(m)	-$6.14M	(m)	(m)	(m)	$582.00K*	-$4.96M*	(m)	(m)	(m)	(m)
2021-06-30	Reported	(m)	-$6.20M	(m)	(m)	(m)	$196.00K*	-$4.54M*	(m)	(m)	(m)	(m)
2021-03-31	Reported	(m)	-$5.43M	(m)	(m)	(m)	$298.00K	-$5.47M	(m)	(m)	(m)	(m)
2020-09-30	Reported	(m)	-$5.62M	(m)	(m)	(m)	$81.00K*	-$3.88M*	(m)	(m)	(m)	(m)
2020-06-30	Reported	(m)	-$4.59M	(m)	(m)	(m)	$273.00K*	-$3.86M*	(m)	(m)	(m)	(m)
2020-03-31	Reported	(m)	-$4.92M	(m)	(m)	(m)	$104.00K	-$4.23M	(m)	(m)	(m)	(m)
2019-09-30	Reported	(m)	-$6.78M	(m)	(m)	(m)	-$65.00K*	-$4.57M*	(m)	(m)	(m)	(m)
2019-06-30	Reported	(m)	-$5.16M	(m)	(m)	(m)	$126.00K*	-$5.83M*	(m)	(m)	(m)	(m)
2019-03-31	Reported	(m)	-$3.44M	(m)	(m)	(m)	$142.00K	-$2.46M	(m)	$1.49M	(m)	(m)
2018-09-30	Reported	(m)	-$2.43M	(m)	(m)	(m)	$155.00K*	-$2.02M*	(m)	$361.00K	(m)	(m)
2018-06-30	Reported	(m)	-$2.84M	(m)	(m)	(m)	(m)	-$1.88M*	(m)	$1.69M	(m)	(m)
2018-03-31	Reported	(m)	-$3.06M	(m)	(m)	(m)	(m)	-$3.54M	(m)	$1.46M	(m)	(m)
2017-09-30	Reported	(m)	-$746.00K	(m)	(m)	(m)	$33.00K*	-$593.00K*	(m)	-$829.00K*	(m)	$0.00*
2017-06-30	Reported	(m)	-$9.69M	(m)	(m)	(m)	$2.00K*	-$2.93M*	(m)	$1.13M	(m)	-$1.30M
2017-03-31	Reported	(m)	-$3.36M	(m)	(m)	(m)	$5.00K	-$3.30M	(m)	$1.49M	(m)	(m)
2016-12-31	Reported	(m)	-$11.86M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-09-30	Reported	(m)	-$3.41M	(m)	(m)	(m)	$29.00K*	(m)	(m)	$1.66M	(m)	(m)
2016-06-30	Reported	(m)	-$3.59M	(m)	(m)	(m)	$125.00K*	(m)	(m)	$1.24M	(m)	(m)
2016-03-31	Reported	(m)	-$4.52M	(m)	(m)	(m)	$112.00K	(m)	(m)	$1.98M	(m)	(m)
2015-12-31	Reported	(m)	-$2.94M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	-$73.00K
2015-09-30	Reported	(m)	-$2.43M	(m)	(m)	(m)	$116.00K*	(m)	(m)	$728.00K	(m)	(m)
2015-06-30	Reported	(m)	-$2.59M	(m)	(m)	(m)	$9.00K*	(m)	(m)	$1.08M	(m)	(m)
2015-03-31	Reported	(m)	-$2.27M	(m)	(m)	(m)	$35.00K	(m)	(m)	$972.00K	(m)	(m)
2014-12-31	Reported	(m)	-$2.60M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2014-09-30	Reported	(m)	-$5.23M	(m)	(m)	(m)	$137.00K*	(m)	(m)	$1.79M	(m)	(m)
2014-06-30	Reported	(m)	-$3.75M	(m)	(m)	(m)	$831.00K*	(m)	(m)	$1.89M	(m)	(m)
2014-03-31	Reported	(m)	-$2.53M	(m)	(m)	(m)	$229.00K	(m)	(m)	$1.01M	(m)	(m)
2013-09-30	Reported	(m)	-$2.34M	(m)	(m)	(m)	$32.00K*	(m)	(m)	$1.12M	(m)	(m)
2013-06-30	Reported	(m)	-$6.12M	(m)	(m)	(m)	$65.00K*	(m)	(m)	$3.60M	(m)	(m)
2013-03-31	Reported	(m)	-$1.33M	(m)	(m)	(m)	$0.00	(m)	(m)	$641.00K	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	(m)	-$36.63M	(m)	(m)	(m)	$542.00K	-$25.76M	(m)	(m)	(m)	(m)
2024-12-31	Reported	-$41.11M	(m)	(m)	(m)	(m)	$1.88M	-$37.55M	(m)	(m)	(m)	(m)
2023-12-31	Reported	-$39.92M	(m)	(m)	(m)	(m)	$8.14M	-$47.42M	(m)	(m)	(m)	(m)
2022-12-31	Reported	-$36.05M	(m)	(m)	(m)	(m)	$2.21M	-$32.48M	(m)	(m)	(m)	(m)
2021-12-31	Reported	(m)	-$23.82M	(m)	(m)	(m)	$1.30M	-$23.57M	(m)	(m)	(m)	(m)
2020-12-31	Reported	(m)	-$21.59M	(m)	(m)	(m)	$824.00K	-$18.27M	(m)	(m)	(m)	(m)
2019-12-31	Reported	(m)	-$19.75M	(m)	(m)	(m)	$224.00K	-$15.58M	(m)	$9.82M	(m)	(m)
2018-12-31	Reported	(m)	-$17.66M	(m)	(m)	(m)	$875.00K	-$10.63M	(m)	$8.37M	(m)	-$328.00K
2017-12-31	Reported	(m)	-$16.16M	(m)	(m)	(m)	$58.00K	-$9.19M	(m)	$2.88M	(m)	-$1.30M
2017-09-30	Rolling	(m)	-$25.66M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-06-30	Rolling	(m)	-$28.32M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-03-31	Rolling	(m)	-$22.22M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-12-31	Reported	(m)	-$23.38M	(m)	(m)	(m)	$279.00K	-$10.61M	(m)	$5.68M	(m)	-$556.00K
2016-12-31	Rolling	(m)	-$23.38M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-09-30	Rolling	(m)	-$14.45M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-06-30	Rolling	(m)	-$13.47M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-03-31	Rolling	(m)	-$12.48M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-12-31	Reported	(m)	-$10.23M	(m)	(m)	(m)	$210.00K	(m)	(m)	$3.99M	(m)	-$73.00K
2015-12-31	Rolling	(m)	-$10.23M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-09-30	Rolling	(m)	-$9.88M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-06-30	Rolling	(m)	-$12.69M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-03-31	Rolling	(m)	-$13.84M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2014-12-31	Reported	(m)	-$14.11M	(m)	(m)	(m)	$1.20M	(m)	(m)	$5.80M	(m)	(m)
2014-12-31	Rolling	(m)	-$14.11M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2013-12-31	Reported	(m)	-$12.38M	(m)	(m)	(m)	$102.00K	(m)	(m)	$6.47M	(m)	(m)

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Neumora Therapeutics, Inc. (NMRA)	United States	$0.132B	-1.48
Caribou Biosciences, Inc. (CRBU)	United States	$0.134B	-1.79
enGene Therapeutics Inc. (ENGN)		$0.129B	-0.92
Tenaya Therapeutics, Inc. (TNYA)	United States	$0.140B	-1.60
LENZ Therapeutics, Inc. (LENZ)	United States	$0.117B	-1.41
Humacyte, Inc. (HUMA)	United States	$0.155B	-2.26
Black Diamond Therapeutics, Inc. (BDTX)	United States	$0.109B	-2.48
Outlook Therapeutics, Inc. (OTLK)	United States	$0.162B	-4.90
Acumen Pharmaceuticals, Inc. (ABOS)	United States	$0.162B	-1.83
Cardiff Oncology, Inc. (CRDF)	United States	$0.101B	-2.22